The estimated Net Worth of Harout Der Simonian is at least 40.3 千$ dollars as of 12 October 2016. Mr. Simonian owns over 10,000 units of Biostage stock worth over 40,300$ and over the last 8 years he sold BSTG stock worth over 0$. In addition, he makes 0$ as Chief Scientific Officer at Biostage.
Harout has made over 1 trades of the Biostage stock since 2016, according to the Form 4 filled with the SEC. Most recently he bought 10,000 units of BSTG stock worth 9,100$ on 12 October 2016.
The largest trade he's ever made was buying 10,000 units of Biostage stock on 12 October 2016 worth over 9,100$. On average, Harout trades about 10,000 units every 0 days since 2016. As of 12 October 2016 he still owns at least 10,000 units of Biostage stock.
You can see the complete history of Mr. Simonian stock trades at the bottom of the page.
Harout DerSimonian is Chief Scientific Officer of the Company. He has over 20 years of experience in developing immunotherapy and cell therapy programs and was instrumental in directing the science that enabled the first FDA-approved clinical trial using autologous human stem cells for cardiac repair. Throughout his career, he has played a critical, senior role in designing and implementing therapeutic programs at leading global institutions. Dr. DerSimonian is a former assistant professor and post-doctoral fellow atHarvard Medical Schooland completed his post-doctoral training at the Dana-Faber Cancer Institute and Brigham and Women's Hospital. Dr. DerSimonian holds a Ph.D. in immunology from Tufts University and a B.A. in biology from Hartwick College.
Harout's mailing address filed with the SEC is C/O BIOSTAGE, INC., 84 OCTOBER HILL ROAD, SUITE 11, HOLLISTON, MA, 01746.
Over the last 9 years, insiders at Biostage have traded over 962,849$ worth of Biostage stock and bought 1,593,581 units worth 3,804,230$ . The most active insiders traders include David Green、Capital Llc Dst、Ronald J Packard. On average, Biostage executives and independent directors trade stock every 79 days with the average trade being worth of 217,604$. The most recent stock trade was executed by Capital Llc Dst on 6 April 2023, trading 62,500 units of BSTG stock currently worth 375,000$.
Biostage, Inc., a biotechnology company, engages in developing bioengineered organ implants based on its Cellframe technology. The company's Cellframe technology comprises a biocompatible scaffold that is seeded with the recipient's own stem cells. It is developing its Cellframe technology to treat life-threatening conditions of the esophagus, bronchus, or trachea. The company was formerly known as Harvard Apparatus Regenerative Technology, Inc. and changed its name to Biostage, Inc. in March 2016. Biostage, Inc. was founded in 2007 and is headquartered in Holliston, Massachusetts.
Biostage executives and other stock owners filed with the SEC include: